Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
58 hedge funds and large institutions have $94.3M invested in Eidos Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 14 closing their positions.
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
29% more funds holding
Funds holding: 45 → 58 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
46% less capital invested
Capital invested by funds: $174M → $94.3M (-$79.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$11.1M |
| 2 |
BlackRock
New York
|
+$9.5M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$4.6M |
| 4 |
AIG
American International Group
New York
|
+$3.94M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$6.51M |
| 2 |
Millennium Management
New York
|
-$5.71M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$4.31M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.29M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.95M |
EIDX Hedge Fund Activity: Q3 2018 in Review
58 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q3 2018, worth a combined $94.3M — down 46% from $174M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new EIDX positions and 14 closed out — a net gain of 13 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Redmile Group, adding an estimated $11.1M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.51M sold.
- 58 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q3 2018, up from 45 in Q2 2018.
- Funds reported $94.3M of Eidos Therapeutics, Inc. Common Stock stock for Q3 2018, down 46% quarter-over-quarter.
- 27 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q3 2018 and 14 closed out, a net change of +13 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q3 2018 was Redmile Group, an estimated $11.1M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q3 2018 was Janus Henderson Group, an estimated $6.51M sold.
Based on aggregated 13F filings for Q3 2018.